BIOA - NASDAQ

BL

BioAge Labs, Inc.

BIOAยทNASDAQ

$16.04

-3.0%
HealthcareBiotechnology

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$603.90M
EPS-2.2400
P/E Ratio-7.16
Earnings Date08/05/2026
BL

BioAge Labs, Inc. Fair Value Envelope

BIOA ยท NASDAQ

Our analysis suggests that BIOA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.04, this represents a potential HIDDEN relative to our calculated worth for BioAge Labs, Inc..

HIDDEN
Intrinsic Value
Current Price: $16.04

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$70.5M
+ Cash & Equivalents$188.9M
Firm Value$118.4M
- Debt$5.6M
Equity Value$112.9M
/ Shares Outstanding35,850,037B
DCF Value$3
OVERVALUED BY 80%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$40.8M
-$20.4M
-$10.2M
-$5.1M
-$2.6M
-$1.3M
-$637.7K
-$318.9K
-$159.4K
-$79.7K
Maintenance CapEx
-$71.9K
-$36.0K
-$18.0K
-$9.0K
-$4.5K
-$2.2K
-$1.1K
-$562
-$281
-$140
Owner Earnings
-$40.9M
-$20.4M
-$10.2M
-$5.1M
-$2.6M
-$1.3M
-$638.8K
-$319.4K
-$159.7K
-$79.9K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$37.9M
-$17.5M
-$8.1M
-$3.8M
-$1.7M
-$805.1K
-$372.8K
-$172.6K
-$79.9K
-$37.0K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your BIOA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.